SHORT REPORT Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer’s disease
نویسندگان
چکیده
Objective: Brain acetylcholinesterase activity was determined in healthy controls and in patients with mild cognitive impairment and early Alzheimer’s disease. Methods: A specific acetylcholinesterase tracer, [methylC]N-methyl-piperidyl-4-acetate ([C]MP4A), and a three dimensional PET system with magnetic resonance coregistration were used for imaging. Results: There was a significant difference in the acetylcholinesterase activity in the hippocampus between the groups (p = 0.03), the mean (SD) acetylcholinesterase activity (k3 values, min) being 0.114 (0.036) in controls, 0.098 (0.023) in mild cognitive impairment, and 0.085 (0.022) in Alzheimer’s disease. The mini-mental state examination score showed no significant relation with acetylcholinesterase activity in any brain area in the combined mild cognitive impairment/Alzheimer group. Conclusions: Hippocampal acetylcholinesterase activity is only slightly reduced in mild cognitive impairment and early Alzheimer’s disease and so the value of in vivo acetylcholinesterase measurements in detecting the early Alzheimer process is limited.
منابع مشابه
Identification of mild cognitive impairment disease using brain functional connectivity and graph analysis in fMRI data
Background: Early diagnosis of patients in the early stages of Alzheimer's, known as mild cognitive impairment, is of great importance in the treatment of this disease. If a patient can be diagnosed at this stage, it is possible to treat or delay Alzheimer's disease. Resting-state functional magnetic resonance imaging (fMRI) is very common in the process of diagnosing Alzheimer's disease. In th...
متن کاملCurrent evidence of the impact of acetylcholinesterase inhibitors on mild cognitive impairment and vascular dementia
Introduction: Acetylcholinesterase inhibitors constitute an effective class of drugs for the treatment of mild and moderate Alzheimer’s disease and are allowed by the responsible agencies for this purpose only. However, concrete evidence is still necessary in what concerns the impact of the use of such drugs to treat a large variety of cognitive disorders not classified as Alzheimer’sdi...
متن کاملChanges in Catecholamines and Acetylcholinesterase Levels of Crebellum, Mid-brain and Brain Cortex in Chromium Treated Rats
The short and long term effects of chromium toxicity on brain catecholamines and acetylcholinesterase levels were investigated. Rats were injected daily with varying amounts of chromium. The short term (2 h) administration of chromium (8 mmol/kg) reduced catecholamines level of cerebellum, mid-brain and brain-cortex by 22.8, 19.4 and 21.2% respectively. Acetylcholinesterase activity was also re...
متن کاملChanges in Catecholamines and Acetylcholinesterase Levels of Crebellum, Mid-brain and Brain Cortex in Chromium Treated Rats
The short and long term effects of chromium toxicity on brain catecholamines and acetylcholinesterase levels were investigated. Rats were injected daily with varying amounts of chromium. The short term (2 h) administration of chromium (8 mmol/kg) reduced catecholamines level of cerebellum, mid-brain and brain-cortex by 22.8, 19.4 and 21.2% respectively. Acetylcholinesterase activity was also re...
متن کاملSynthesis and acetylcholinesterase inhibitory evaluation of 4-(1,3-Dioxoisoindolin-2-yl)-N-phenylbenzamide derivatives as potential anti-alzheimer agents
Patients with Alzheimer's disease have cognitive deficits, impaired long-term potentiation and learning and memory. A progressive reduction in cholinergic neurons in some areas of the brain such as cortex and hippocampus is related to the deficits in memory and cognitive function in Alzheimer’s disease (AD). In the current project a new series of phthalimide derivatives were synthesized. Phthal...
متن کامل